Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Edsivo
Synonyms :
celiprolol
Class :
Beta-Blockers, Beta2 Agonists,Beta-1 Selective
Brand Name :
Edsivo
Synonyms :
celiprolol
Class :
Beta-Blockers, Beta2 Agonists,Beta-1 Selective
Pending FDA ApprovalÂ
Pending FDA ApprovalÂ
may decrease the therapeutic effect when combined with methacholine
may have an increasingly adverse effect when combined with other beta2-agonists
may have an increasingly adverse effect when combined with other beta2-agonists
may have an increasingly adverse effect when combined with other beta2-agonists
may have an increasingly adverse effect when combined with other beta2-agonists
may have an increasingly adverse effect when combined with other beta2-agonists
may have an increased hypokalemic effect when combined with loop diuretics
may have an increased hypokalemic effect when combined with loop diuretics
may have an increased hypokalemic effect when combined with loop diuretics
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with other beta2-agonists
may have an increasingly adverse effect when combined with other beta2-agonists
may have an increasingly adverse effect when combined with other beta2-agonists
may have an increasingly adverse effect when combined with other beta2-agonists
may have an increasingly adverse effect when combined with other beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
beta2 agonist bronchodilation may be reduced with beta2 blockers
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may increase the adverse effect of monoamine oxidase inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
it may diminish the metabolism when combined with azelastine
celiprolol: they may enhance the serum concentration of glycoprotein Inhibitors
celiprolol: they may enhance the serum concentration of CYP2D6 Inhibitors
celiprolol: they may enhance the serum concentration of CYP2D6 Inhibitors
celiprolol: they may enhance the serum concentration of CYP2D6 Inhibitors
celiprolol: they may enhance the serum concentration of CYP2D6 Inhibitors
celiprolol: they may enhance the serum concentration of CYP2D6 Inhibitors
When ponesimod is used together with celiprolol, this leads to enhanced risk or seriousness of bradycardia
may increase the hypokalemic effect when combined with thiazide diuretics
may increase the hypokalemic effect when combined with thiazide diuretics
When celiprolol is used together with givinostat, this leads to enhanced risk or seriousness of Qtc prolongation
When indisulam is used together with celiprolol, this leads to a reduction in celiprolol metabolism
celiprolol: it may increase the risk or severity of CNS depression
celiprolol: it may increase the risk or severity of CNS depression
celiprolol: it may increase the risk or severity of CNS depression
celiprolol: it may increase the risk or severity of CNS depression
celiprolol: it may increase the risk or severity of CNS depression
celiprolol: it may increase the risk of adverse effects of oxtriphylline
celiprolol: it may decrease the therapeutic efficacy of procaterol
celiprolol: it may increase the arrhythmogenic activities of caroverine
celiprolol: it may increase the risk of methemoglobinemia associated agents
celiprolol: it may increase the risk of methemoglobinemia associated agents
celiprolol: it may increase the risk of methemoglobinemia associated agents
celiprolol: it may increase the risk of methemoglobinemia associated agents
celiprolol: it may increase the risk of methemoglobinemia associated agents
celiprolol: it may increase the risk of adverse effects with arecoline
may enhance the serum concentration
may enhance the serum concentration
eprosartan/hydrochlorothiazideÂ
may increase the toxic effect of thiazide and thiazide like diuretics
moexipril/hydrochlorothiazideÂ
may increase the hypokalaemia effect of thiazide and thiazide like diuretics
may enhance the serum concentration of P-glycoprotein/ABCB1 inhibitors
may have an increasingly adverse effect when combined with atosiban
may increase the effects of bosentan by pharmacodynamic synergism
atomoxetine: they may increase the tachycardic effect of Beta2-Agonists
Monoamine Oxidase Inhibitors: they may increase the toxic effect of Beta2-Agonists
Monoamine Oxidase Inhibitors: they may increase the toxic effect of Beta2-Agonists
Monoamine Oxidase Inhibitors: they may increase the toxic effect of Beta2-Agonists
Monoamine Oxidase Inhibitors: they may increase the toxic effect of Beta2-Agonists
Monoamine Oxidase Inhibitors: they may increase the toxic effect of Beta2-Agonists
hypokalemic effects of thiazide-like derivatives can be increased with beta2 agonists
hypokalemic effects of thiazide-like derivatives can be increased with beta2 agonists
hypokalemic effects of thiazide-like derivatives can be increased with beta2 agonists
hypokalemic effects of thiazide-like derivatives can be increased with beta2 agonists
adverse effects of beta2 agonists are increased with tricyclic antidepressants
the therapeutic activity of celiprolol may be reduced
When celiprolol is used together with oliceridine, this leads to reduction in oliceridine’s metabolism
may decrease the bronchodilatory effect when combined with Beta2-Agonists
may decrease the bronchodilatory effect when combined with Beta2-Agonists
may decrease the bronchodilatory effect when combined with Beta2-Agonists
may decrease the bronchodilatory effect when combined with Beta2-Agonists
Action and spectrum:Â
The action of celiprolol is to block the effects of adrenaline and other stress hormones on the heart and blood vessels. By doing so, it helps to reduce the workload on the heart and lower blood pressure, thus improving blood flow to the body’s organs and tissues.Â
celiprolol is selective for beta-1 receptors, which are primarily found in the heart. This means that it has a lower risk of causing side effects associated with non-selective beta-blockers, such as bronchoconstriction and worsening of asthma symptoms.Â
Â
Limited information
None
Contraindication / CautionÂ
Contraindications:Â
Precautions:Â
Â
Pregnancy warnings:   
Pregnancy category: N/A
Lactation:Â Excreted into human milk is unknown
Pregnancy Categories:     
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus in either the first or second trimester.
Category B: There were lack of studies on pregnant women and no evidence of risk to the foetus in animal experiments.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Pharmacology:Â
The pharmacology of celiprolol is characterized by its selective beta-1 adrenergic receptor blocking activity, which means that it has a greater affinity for the beta-1 receptors found in the heart and less activity at the beta-2 receptors found in the lungs and blood vessels. This selectivity reduces the risk of adverse effects on the respiratory system and peripheral circulation.Â
Pharmacodynamics:Â
celiprolol also has intrinsic sympathomimetic activity (ISA), which means that it has a partial agonist effect on beta receptors. This allows for a more gradual reduction in heart rate and blood pressure compared to other beta-blockers. Additionally, celiprolol has membrane stabilizing activity, which may contribute to its antiarrhythmic effects.Â
Pharmacokinetics:Â
AbsorptionÂ
celiprolol is well-absorbed orally, with peak plasma concentrations occurring 1 to 3 hours after ingestion. Food does not significantly affect its absorption.Â
DistributionÂ
celiprolol has a high volume of distribution (Vd) of about 3.5 L/kg, indicating extensive tissue distribution. It is approximately 50% bound to plasma proteins.Â
MetabolismÂ
celiprolol is primarily metabolized in the liver by CYP2D6 to form an active metabolite, which has similar beta-blocking properties to celiprolol itself. Approximately 70% of an oral dose of celiprolol is metabolized via this pathway. Celiprolol is also metabolized via glucuronidation.Â
Elimination and ExcretionÂ
celiprolol and its metabolites are primarily excreted in the urine (70-80%) and feces (20-30%), with an elimination half-life of about 2 to 4 hours in healthy individuals. Renal clearance is the major route of elimination.Â
Â
Administration:Â
The administration of celiprolol should be carried out according to the instructions of a healthcare professional. The recommended dosage of celiprolol may vary depending on the individual’s condition, age, weight, and other factors.Â
celiprolol is typically taken orally, with or without food, once or twice daily. It is important to take the medication at the same time(s) each day to maintain a consistent level of the drug in the bloodstream.Â
Patient information leafletÂ
Generic Name: celiprololÂ
Why do we use celiprolol?Â
celiprolol is a medication that belongs to a class of drugs known as beta-blockers. It is used to treat a variety of conditions, including:Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
